IONS Ionis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IONS

Price (delayed)

$75.12

Market cap

$12.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.01

Enterprise value

$14.28B

?
Relative Growth: Rel. Growth: 80
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 40

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights
IONS's revenue is up by 48% YoY and by 12% QoQ
The gross profit is up by 47% year-on-year and by 12% since the previous quarter
IONS's quick ratio has dropped by 68% year-on-year and by 21% since the previous quarter
The company's debt rose by 45% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.ionispharma.com/

Key stats

What are the main financial stats of IONS

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
1.76%
1 week
-2.86%
1 month
-0.44%
1 year
113.96%
YTD
-5.04%
QTD
0.04%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$1.06B
Gross profit
$1.04B
Operating income
-$352.25M
Net income
-$326.98M
Gross margin
98.4%
Net margin
-30.9%
The company's net margin has surged by 52% YoY and by 24% QoQ
The operating margin is up by 49% year-on-year and by 18% since the previous quarter
IONS's revenue is up by 48% YoY and by 12% QoQ
The gross profit is up by 47% year-on-year and by 12% since the previous quarter

Price vs fundamentals

How does IONS's price correlate with its fundamentals

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
IONS P/E details
P/E
N/A
P/B
25.25
P/S
11.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.5
Ionis Pharmaceuticals's EPS has increased by 33% YoY and by 16% QoQ
The stock's price to book (P/B) is 79% more than its 5-year quarterly average of 13.9 and 27% more than its last 4 quarters average of 19.6
The company's equity rose by 3.3% YoY
IONS's revenue is up by 48% YoY and by 12% QoQ
The P/S is 37% more than the 5-year quarterly average of 8.4 and 8% more than the last 4 quarters average of 10.6

Efficiency

How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has surged by 57% YoY and by 27% QoQ
Ionis Pharmaceuticals's ROIC has increased by 38% YoY and by 23% from the previous quarter
IONS's return on assets is up by 36% year-on-year and by 18% since the previous quarter
IONS's return on equity is up by 36% year-on-year and by 15% since the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 17% greater than the total liabilities
IONS's quick ratio has dropped by 68% year-on-year and by 21% since the previous quarter
The current ratio has dropped by 58% year-on-year but it rose by 7% since the previous quarter
The company's debt rose by 45% YoY
Ionis Pharmaceuticals's debt to equity has increased by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.